Non Hodgkin Lymphoma Clinical Trial

Study of Nivolumab in Patients With Classical Hodgkin’s Lymphoma (Registrational)

Summary

The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B & C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma participants.

View Eligibility Criteria

Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Must have received prior high-dose conditioning chemotherapy followed by autologous stem cell transplant (ASCT) as a part of salvage therapy for cHL (cohort A, B & C - enrollment closed)
Participants may be Brentuximab vedotin- naïve, or may have had prior Brentuximab vedotin treatment (cohort A, B & C - enrollment closed)
Newly diagnosed and previously untreated classical Hodgkin Lymphoma (cohort D)

Exclusion Criteria:

Known central nervous system lymphoma
Participants with nodular lymphocyte-predominant Hodgkin Lymphoma
Prior allogeneic stem cell transplantation (SCT)
Chest radiation ≤ 24 weeks prior to first dose
Carmustine ≥ 600 mg/m² received as part of the pre-transplant conditioning regimen

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

294

Study ID:

NCT02181738

Recruitment Status:

Active, not recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 36 Locations for this study

See Locations Near You

Local Institution - 0030
Los Angeles California, 90048, United States
Local Institution - 0009
Los Angeles California, 90095, United States
Local Institution - 0001
Atlanta Georgia, 30322, United States
Local Institution - 0002
Boston Massachusetts, 02215, United States
Local Institution - 0025
Boston Massachusetts, 02215, United States
Local Institution - 0041
Boston Massachusetts, 02215, United States
Local Institution - 0008
Detroit Michigan, 48201, United States
Local Institution - 0003
Rochester Minnesota, 55905, United States
Local Institution - 0040
Basking Ridge New Jersey, 07920, United States
Local Institution - 0047
Hackensack New Jersey, 07601, United States
Local Institution - 0005
New York New York, 10021, United States
Local Institution - 0006
Allentown Pennsylvania, 18103, United States
Local Institution - 0004
Nashville Tennessee, 37232, United States
Local Institution - 0007
Houston Texas, 77030, United States
Local Institution - 0032
Innsbruck , 6020, Austria
Local Institution - 0031
Wien , 1090, Austria
Local Institution - 0014
B-leuven , 3000, Belgium
Local Institution - 0015
Gent , 9000, Belgium
Local Institution - 0046
Vancouver British Columbia, V5Z 4, Canada
Local Institution - 0042
Toronto Ontario, M5G 2, Canada
Local Institution - 0044
Praha 2 , 128 0, Czechia
Local Institution - 0037
Berlin , 10117, Germany
Local Institution - 0036
Hamburg , 20099, Germany
Local Institution - 0033
Koeln , 50937, Germany
Local Institution - 0034
Ulm , 89081, Germany
Local Institution - 0019
Bologna , 40126, Italy
Local Institution - 0020
Napoli , 80131, Italy
Local Institution - 0035
Rozzano (milano) , 20089, Italy
Local Institution - 0016
Amsterdam , 1066 , Netherlands
Local Institution - 0038
Groningen , 9713 , Netherlands
Local Institution - 0017
Utrecht , 3584 , Netherlands
Local Institution - 0023
Marbella Malaga, 29600, Spain
Local Institution - 0022
Hospitalet Llobregat- Barcelona , 9908, Spain
Local Institution - 0027
Majadahonda - Madrid , 28222, Spain
Local Institution - 0043
Swansea Carmarthenshire, SA2 8, United Kingdom
Local Institution - 0012
Withington Manchester, M20 4, United Kingdom
Local Institution - 0026
Oxford Oxfordshire, OX3 7, United Kingdom
Local Institution - 0013
Sutton , SM2 5, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

294

Study ID:

NCT02181738

Recruitment Status:

Active, not recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.